Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

PATHWAY ONTOLOGY - ANNOTATIONS

The Pathway Ontology (PW), is currently being developed at the Rat Genome Database. For more information about this vocabulary, please see Petri et al. The rat genome database pathway portal. Database (Oxford). 2011 Apr 8;2011:bar010. Print 2011 or contact us (http://rgd.mcw.edu/contact/index.shtml).
Term:repaglinide pharmacokinetics pathway
go back to main search page
Accession:PW:0000726 term browser browse the term
Definition:The pathway of processing - absorption, distribution, metabolism or elimination - of repaglinide. The drug is used as an inhibitor of ATP-dependent potassium channel. By blocking the channel it stimulates insulin secretion to lower blood glucose level. Genetic variations can result in changes in the availability of the drug.
View Interactive Diagram

GViewer not supported for the selected species.

show annotations for term's descendants           Sort by:
repaglinide pharmacokinetics pathway term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP2C8 cytochrome P450 family 2 subfamily C member 8 ISO RGD PMID:17253883 RGD:2316509 NCBI chr 9:88,154,131...88,183,915
Ensembl chr 9:88,154,134...88,183,458 		JBrowse link
G LOC103246766 cytochrome P450 3A8 ISO RGD PMID:17253883 RGD:2316509 NCBI chr28:13,297,566...13,330,023 JBrowse link
G SLCO1B1 solute carrier organic anion transporter family member 1B1 ISO RGD PMID:17253883 RGD:2316509 NCBI chr11:20,992,353...21,091,761
Ensembl chr11:21,001,655...21,093,278 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  pathway 4027
    drug pathway 383
      alimentary tract and metabolism drug pathway 81
        anti-diabetic drug pathway 16
          repaglinide pharmacokinetics pathway 3
paths to the root